Navigation Links
Hard To Treat Diseases (HTDS) Slavica BioChem Update on Research Activities
Date:4/22/2009

BELGRADE, April 22 /PRNewswire-FirstCall/ - Hard To Treat Diseases (HTDS) www.htdsmedical.com - HTDS chief scientist Dr. Sanja Pekovic provided updates from a recent medical convention held in Antwerpen; Joint Meeting 2009 Anatomische Gesellschaft - Nederlandse Anatomen Vereniging, Antwerpen, 27-30 March 2009.

Dr. Pekovic reported on the results of recent positive testing being conducted related to the CNS disorder multiple sclerosis and in suppression of reactive astrogliosis after brain injury. This led to a number of preliminary talks for future collaboration with other scientists working in the field. A more detailed review of the research results will be posted separately on the Pink Sheets as a supplementary filing shortly. Notably, this work was supported by the European Cooperation in the Field of Scientific and Technical Research (COST) organization.

Dr. Pekovic also reported the scientific team has started some in vitro studies of purine nucleoside analogues (ribavirin, tiazofurin, the drugs we are investigating) effects on microglial cell culture (there is no current data in the literature about their effect on microglia) in collaboration with professor Thomas Herdegen from Kiel University, Germany, who is also a member of COST as a representative of Germany. Over the last 3 months in the lab, our technicians have learned how to establish microglial cell culture, a valuable next step in the continued research.

HTDS will be providing additional funding to further this work, at the IBISS INSTITUT ZA BIOLOSKA ISTRAZIVANJA SINISA STANKOVIC for Project 143005 headed by professor Mirjana Stojiljkovic.

Safe Harbor Statement

Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard To Treat Diseases Inc that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. Hard To Treat Diseases Inc cautions you that any forward-looking information provided by or on behalf of Hard To Treat Diseases Inc is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard To Treat Diseases Inc's actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard To Treat Diseases Inc's control. In addition to those discussed in Hard To Treat Diseases Inc's press releases, public filings, and statements by Hard To Treat Diseases Inc's management, including, but not limited to, Hard To Treat Diseases Inc's estimate of the sufficiency of its existing capital resources, Hard To Treat Diseases Inc's ability to raise additional capital to fund future operations, Hard To Treat Diseases Inc's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard To Treat Diseases Inc's capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard To Treat Diseases Inc does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact corporate@htdsmedical.com, www.htdsmedical.com


'/>"/>
SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. New treatment shows promise against recurrent gynecologic cancers
2. Leading Critical Care Doctor Shifts From Treatment to Empowerment by Helping Americans Create Optimal Health in Their Lives
3. First Patients in United States Receive Innovative Device to Treat Moderate Heart Failure
4. Surveyed Specialists Foresee Greater Use of Parenteral Outpatient Therapy for the Treatment of Osteomyelitis
5. Canadian Medical Device Set to Speed Treatment and Cut Health Care Costs for Common Cause of Vertigo
6. Mayo Clinic researchers formulate treatment combination lethal to pancreatic cancer cells
7. Yashoda Cancer Institute Treats First Patient in India Using RapidArc Radiotherapy Technology
8. For Reducing Mortality, Current and Emerging Therapies Have No Advantage Over Carvedilol in the Treatment of Coronary Heart Disease (Stable Angina)
9. Targeted Treatments Show Mettle Against Advanced Cancers
10. North Carolina Give Kids A Smile! Project Treats Close to 20,000 Children
11. Treatment Algorithm Helps Successfully Manage Diabetes after Transplant Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... September 20, 2017 , ... “The Financial Favor of God; Second Edition”: a ... Second Edition” is the creation of published author, Brooks Rathell. , “We typically hear ... to you about the financial favor of God. Not only does it exist, but ...
(Date:9/19/2017)... ... September 19, 2017 , ... Only a few physicians were selected to receive ... Ross A. Clevens, MD, FACS . The founder and medical director of Clevens ... who trained at Yale, Harvard and the University of Michigan. He has served patients ...
(Date:9/19/2017)... ... September 19, 2017 , ... Peter ... the President’s Malaria Initiative (PMI) Africa Indoor Residual Spraying (AIRS) Project , ... , The Innovation to Action Award, a USAID Catalyst Award, recognizes USAID ...
(Date:9/19/2017)... ... September 19, 2017 , ... The ... Canyon Ranch to its recently formed Corporate Roundtable, a group of individuals ... and a sustainable world. , Canyon Ranch is a unique collection of lifestyle-based ...
(Date:9/19/2017)... ... September 19, 2017 , ... Leonard I. Linkow, DDS, DMSC, sets a new ... Xlibris on July of 2014). This book details the recent advances and techniques in ... benefit people who have lost all of their natural teeth . , In ...
Breaking Medicine News(10 mins):
(Date:9/5/2017)...  Getinge, a leading global provider of innovative ... program -- "Color for the Kids!" -- to ... by The Children,s Heart Foundation. Pediatric patients and ... encouraged to download a coloring picture at ... the gallery on the website. For each artwork ...
(Date:9/1/2017)... , Sept. 1, 2017  Bayer will present the ... European Society for Medical Oncology (ESMO) 2017 Congress, September 8-12 ... will include new preclinical and clinical data on Bayer,s marketed ... earlier pipeline projects. ... best minds in cancer research at ESMO," said Carsten ...
(Date:8/28/2017)... ®, a division of LightScalpel ®, LLC, is announcing its new ... years of American veterinary laser surgery innovation, Aesculight® is revolutionizing veterinary laser ... ... his new VetScalpel laser. Dr. Duclos practices veterinary dermatology at the Animal ... ...
Breaking Medicine Technology: